Acute hemolysis in a patient with a newly diagnosed glioblastoma
نویسندگان
چکیده
منابع مشابه
ROLe Of beVacizumab iN NewLy diagNOsed gLiObLastOma
Chemoradiation (CRT) with temozolomide (TMZ/CRT+TMZ) is the standard of care for newly diagnosed glioblastoma (GBM). This phase III trial, conducted by the Radiation Therapy Oncology Group (RTOG), North Central Cancer Treatment Group (NCCTG) and Eastern Cooperative Oncology Group (ECOG), evaluated whether adding bevacizumab (Bev) to standard CRT improves overall survival (OS) or progression-fre...
متن کاملConditional probability of survival in patients with newly diagnosed glioblastoma.
PURPOSE The disease outcome for patients with cancer is typically described in terms of estimated survival from diagnosis. Conditional probability offers more relevant information regarding survival for patients once they have survived for some time. We report conditional survival probabilities on the basis of 498 patients with glioblastoma multiforme receiving radiation and chemotherapy. For 1...
متن کاملIntravascular Hemolysis Due to Glucose‐6‐Phosphate Dehydrogenase Deficiency in a Patient with Aluminium Phosphide Poisoning
Aluminium Phosphide poisoning and glucose‐6‐phosphate dehydrogenase deficiency are two commonly seen clinical presentations in Iran. However, hemolysis associated with Aluminium Phosphide poisoning is very rare. We report a case of concurrent Aluminium Phosphide poisoning and glucose‐6‐phosphate dehydrogenase deficiency in a 24 year old man presenting with intravascular hemolysis. Key words...
متن کاملA randomized trial of bevacizumab for newly diagnosed glioblastoma
Concurrent treatment with temozolomide and radiotherapy followed by maintenance temozolomide is the standard of care for patients with newly diagnosed glioblastoma. Bevacizumab, a humanized monoclonal antibody against vascular endothelial growth factor A, is currently approved for recurrent glioblastoma. Whether the addition of bevacizumab would improve survival among patients with newly diagno...
متن کاملA randomized trial of bevacizumab for newly diagnosed glioblastoma.
BACKGROUND Concurrent treatment with temozolomide and radiotherapy followed by maintenance temozolomide is the standard of care for patients with newly diagnosed glioblastoma. Bevacizumab, a humanized monoclonal antibody against vascular endothelial growth factor A, is currently approved for recurrent glioblastoma. Whether the addition of bevacizumab would improve survival among patients with n...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: CNS Oncology
سال: 2016
ISSN: 2045-0907,2045-0915
DOI: 10.2217/cns-2015-0009